Last reviewed · How we verify
Beclomethasone Dipropionate 640
Beclomethasone dipropionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs.
Beclomethasone dipropionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Beclomethasone Dipropionate 640 |
|---|---|
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone dipropionate is an inhaled corticosteroid that reduces airway inflammation by activating glucocorticoid receptors, leading to decreased production of inflammatory mediators and recruitment of immune cells. It is used to control and prevent symptoms of asthma and chronic obstructive pulmonary disease (COPD) by reducing airway hyperresponsiveness and mucus production.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Dysphonia
- Tremor
- Headache
- Throat irritation
Key clinical trials
- Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (PHASE3)
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
- Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma (PHASE3)
- A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma (PHASE3)
- Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma (PHASE3)
- Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma (PHASE3)
- Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: